Lacticaseibacillus Rhamnosus LRa05 for Alleviating Allergic Rhinitis in Children

The clinical trial aims to investigate the efficacy of Lactobacillus rhamnosus LRa05 in alleviating allergic rhinitis and its impact on the gut microbiota among 70 pediatric participants aged 4-12. The primary objective is to validate the improvement in allergic rhinitis symptoms following an 8-week intervention with Lactobacillus rhamnosus LRa05. Participants were instructed to consume the probiotic powder daily for approximately 8 weeks. At baseline, week 4, and week 8 endpoints, assessments of nasal symptoms, quality of life questionnaires, and stool samples for microbiota analysis were conducted on the participants, and blood samples were collected for immune-related factor testing.

NCT Number	NCT06699537
Lead Sponsor	Wecare Probiotics Co., Ltd.
Conditions	Allergic Rhinitis (AR)
Enrollment	70 participants
Start Date	2024-12-01
Primary Completion	2025-11-01 (estimated)
Study Completion	2025-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-11-21